Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Chatenay-Malabry, France.
Chemistry Department, Georgetown University, 37th and O Streets, Washington, DC 20057, USA.
Molecules. 2022 Apr 2;27(7):2313. doi: 10.3390/molecules27072313.
There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC value of 0.2 µM against , and a selectivity index value of 187, together with in vivo activity on the /hamster model. Attempts to establish structure-activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.
需要新的、具有成本效益的药物来治疗利什曼病。基于玻利维亚传统医学的策略导致发现了 2-取代喹啉系列,作为具有抗利什曼原虫活性和低毒性的分子的来源。本综述记录了该系列从第一个分离的天然化合物到经过数百个合成分子的发展,直到优化的化合物在体外对 和选择性指数值为 187 时表现出的活性,以及在 /仓鼠模型中的体内活性。描述了尝试建立构效关系的尝试,以及试图确定作用机制的研究。对于后者,该系列的分子似乎作用于多个靶点,可能包括免疫系统,这可以解释在体外药物压力后观察到的缺乏耐药性。我们还展示了纳米技术策略如何通过适应性配方来提高这些药物的价值,以及机制靶向方法如何产生具有更高活性的新化合物。